Revenue: As of FY2025 Q3, the actual value is USD 753 K.EPS: As of FY2025 Q3, the actual value is USD -0.11, beating the estimate of USD -0.1583.EBIT: As of FY2025 Q3, the actual value is USD -22.37 M.<h3>Segment Revenue</h3><ul><li>Product Revenue, Net: $703,000 for the three months ended September 30, 2025, and $950,000 for the nine months ended September 30, 2025.</li><li>Contract Revenue: $50,000 for the three months ended September 30, 2025, and $621,000 for the nine months ended September 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $17.5 million for the three months ended September 30, 2025, and $16.0 million for the nine months ended September 30, 2025.</li><li>Research and Development Expenses: $17.3 million for the three months ended September 30, 2025, and $54.7 million for the nine months ended September 30, 2025.</li><li>Selling, General and Administrative Expenses: $7.6 million for the three months ended September 30, 2025, and $23.6 million for the nine months ended September 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $78.9 million for the nine months ended September 30, 2025.</li><li>Net Cash Used in Investing Activities: $845,000 for the nine months ended September 30, 2025.</li><li>Net Cash Provided by Financing Activities: $4.3 million for the nine months ended September 30, 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Revenue Interest Liability: $20.7 million as of September 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and scale its manufacturing facility to meet potential market demand.</li><li>Non-Core Business: The company is exploring applications of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.</li><li>Priority: The company emphasizes strategies with concrete projections, such as the commercial launch of Symvess and the submission of a supplemental BLA for the ATEV in AV access for hemodialysis in the second half of 2026.</li></ul>

Humacyte | 10-Q: FY2025 Q3 Revenue: USD 753 K